-
TRENDS IN HEALTH TECHNOLOGY ASSESSMENT SUBMISSION TIMELINES IN IRELAND: A THREE-YEAR RETROSPECTIVE ANALYSIS ACROSS THERAPEUTIC AREAS
Aug 11, 2026, 17:16 PM -
COMPARING THE PERFORMANCE OF ESTIMATORS FOR TRANSPORTING TRIAL TREATMENT EFFECTS TO TARGET POPULATIONS UNDER VARYING POSITIVITY: A SIMULATION STUDY
Aug 11, 2026, 17:16 PM -
ECONOMIC EVALUATION OF LOW DOSE ATROPINE FOR PEDIATRIC MYOPIA: A MODEL-BASED SYSTEMATIC REVIEW ACROSS QALY, REFRACTIVE, AND LIFETIME COST OUTCOMES
Aug 11, 2026, 17:16 PM -
SYNTHETIC PATIENT TRAJECTORIES FROM A GENERATIVE MACHINE-LEARNING MODEL: A FRAMEWORK FOR GENERATING POPULATION-ADJUSTED SURVIVAL OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKAEMIA
Aug 11, 2026, 17:16 PM -
LESSONS LEARNED FROM LINKAGES OF THE PHARMO DATA NETWORK AND ITS APPLICATIONS
Aug 11, 2026, 17:16 PM -
HEALTHCARE SYSTEM AND SOCIETAL RESOURCE REQUIREMENTS ASSOCIATED WITH INTRAVENOUS IMMUNOGLOBULIN TREATMENT FOR PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Aug 11, 2026, 17:16 PM -
ASYMMETRIC CONVERGENCE: MFN AND JCA REFORMS RESHAPE GLOBAL ACCESS STRATEGYBUT ALL EYES ARE ON THE US, NOT EUROPE
Aug 11, 2026, 17:16 PM -
DOES YOUR REGULATORY PATHWAY UNDERMINE YOUR JCA? SCENARIO PLANNING FOR EVIDENCE GENERATION
Aug 11, 2026, 17:16 PM -
INTEGRATING PATIENT-REPORTED OUTCOMES INTO THE NATIONAL CLINICAL QUALITY FRAMEWORK IN TURKIYE: OPPORTUNITIES FOR EQ-5D
Aug 11, 2026, 17:16 PM -
ECONOMIC VALUE OF DIRECT-ACTING ANTIVIRAL THERAPIES FOR HEPATITIS C IN ASIA- A SYSTEMATIC REVIEW WITH EVIDENCE GAP ANALYSIS
Aug 11, 2026, 17:16 PM -
EVALUATING THE ROLE AND APPLICATION OF REAL-WORLD EVIDENCE IN NICE ONCOLOGY HEALTH TECHNOLOGY APPRAISALS AND ITS INFLUENCE ON HTA OUTCOMES (2016-2025)
Aug 11, 2026, 17:16 PM -
HEALTH UTILITY VALUES MEASURED BY EQ-5D IN PATIENTS WITH POST-STROKE HEMIPLGIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Aug 11, 2026, 17:16 PM -
QUANTIFYING THE SOCIAL VALUE GAINED FROM THERAPEUTIC INNOVATION IN MULTIPLE MYELOMA IN SPAIN: A MULTIDIMENSIONAL ASSESSMENT
Aug 11, 2026, 17:16 PM -
SYSTEMATIC SCREENING FOR TYPE 2 DIABETES IN AT-RISK INDIVIDUALS: A MARKOV COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS IN FRANCE
Aug 11, 2026, 17:16 PM -
IMPROVING IDENTIFICATION OF PATIENTS ELIGIBLE FOR ENDOGENOUS CUSHING DISEASE TREATMENT THROUGH CLINICAL EXPERTISE AND MACHINE LEARNING
Aug 11, 2026, 17:16 PM -
AN ECONOMIC MODEL OF CATUMAXOMAB FOR MALIGNANT ASCITES IN ENGLAND
Aug 11, 2026, 17:16 PM -
THE COST OF TOO MUCH TREATMENT: CAUSAL EVIDENCE ON POLYPHARMACY AND HEALTHCARE EXPENDITURES AMONG PATIENTS WITH DIABETES
Aug 11, 2026, 17:16 PM -
PERFORMANCE OF AN AI-POWERED DIGITAL PHENOTYPING PLATFORM FOR PATIENT IDENTIFICATION IN THREE CONDITIONS WITH SYSTEMATIC UNDERCOUNTING IN REAL-WORLD DATA
Aug 11, 2026, 17:16 PM -
AI-ASSISTED DENTAL CARIES DETECTION WITH RADIOGRAPHY: AN EARLY ECONOMIC EVALUATION IN ENGLAND
Aug 11, 2026, 17:16 PM -
INFORMING PICO EXPECTATIONS IN RAPIDLY EVOLVING THERAPY AREAS THROUGH PIVOTAL TRIAL DESIGN ANALYSIS
Aug 11, 2026, 17:16 PM
